Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from CASI Pharmaceuticals ( (CASI) ).
On February 3, 2025, CASI Pharmaceuticals received an interim relief order from the Hong Kong International Arbitration Centre in its dispute with Juventas Cell Therapy Ltd. The order allows Juventas to commercialize CNCT19 under certain conditions, while CASI retains the right to market the product. This development impacts CASI’s operations by maintaining its involvement in CNCT19’s commercialization as the company continues to assert its rights and collaborate with Juventas.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products. The company focuses on hematology oncology therapeutics, organ transplant rejection, autoimmune diseases, and other unmet medical needs. CASI operates with a strong market presence in China, leveraging its regulatory and commercial expertise, and aims to expand its influence globally.
YTD Price Performance: -17.45%
Average Trading Volume: 39,114
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $32.97M
See more data about CASI stock on TipRanks’ Stock Analysis page.
